JPWO2020190768A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020190768A5 JPWO2020190768A5 JP2021555491A JP2021555491A JPWO2020190768A5 JP WO2020190768 A5 JPWO2020190768 A5 JP WO2020190768A5 JP 2021555491 A JP2021555491 A JP 2021555491A JP 2021555491 A JP2021555491 A JP 2021555491A JP WO2020190768 A5 JPWO2020190768 A5 JP WO2020190768A5
- Authority
- JP
- Japan
- Prior art keywords
- dsrna
- compound
- oligonucleotide
- independently
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819189P | 2019-03-15 | 2019-03-15 | |
| US62/819,189 | 2019-03-15 | ||
| US201962864797P | 2019-06-21 | 2019-06-21 | |
| US62/864,797 | 2019-06-21 | ||
| US201962951441P | 2019-12-20 | 2019-12-20 | |
| US62/951,441 | 2019-12-20 | ||
| PCT/US2020/022748 WO2020190768A1 (en) | 2019-03-15 | 2020-03-13 | Oligonucleotides for tissue specific apoe modulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022525208A JP2022525208A (ja) | 2022-05-11 |
| JPWO2020190768A5 true JPWO2020190768A5 (ru) | 2023-03-17 |
Family
ID=72520528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021555491A Pending JP2022525208A (ja) | 2019-03-15 | 2020-03-13 | 組織特異的なａｐｏｅ調節のためのオリゴヌクレオチド |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200362341A1 (ru) |
| EP (1) | EP3937951A4 (ru) |
| JP (1) | JP2022525208A (ru) |
| CN (1) | CN113811311A (ru) |
| AU (1) | AU2020239987A1 (ru) |
| CA (1) | CA3133241A1 (ru) |
| WO (1) | WO2020190768A1 (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210115442A1 (en) * | 2019-08-23 | 2021-04-22 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| BR112022021813A2 (pt) * | 2020-04-27 | 2023-01-17 | Alnylam Pharmaceuticals Inc | Composições de agente de apolipoproteína e (apoe) irna e métodos de uso das mesmas |
| CN114716518A (zh) * | 2021-01-06 | 2022-07-08 | 圣诺制药公司 | 一种能够抑制pcsk9表达的分子构造及药物组合物 |
| KR20240040724A (ko) * | 2021-06-22 | 2024-03-28 | 유니버시티 오브 매사추세츠 | IFN-γ 신호 전달 경로 조절을 위한 올리고 뉴클레오티드 |
| WO2023086777A1 (en) * | 2021-11-09 | 2023-05-19 | Children's National Medical Center | Targeting apoe enhances t-cell killing in cancer immunotherapy |
| WO2024073705A1 (en) * | 2022-09-30 | 2024-04-04 | University Of Massachusetts | Ocular delivery of oligonucleotides |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2314691A3 (en) * | 2002-11-14 | 2012-01-18 | Dharmacon, Inc. | Fuctional and hyperfunctional siRNA |
| US20060257851A1 (en) * | 2002-11-26 | 2006-11-16 | Itzhak Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
| US8362229B2 (en) * | 2006-02-08 | 2013-01-29 | Quark Pharmaceuticals, Inc. | Tandem siRNAS |
| JP5524189B2 (ja) * | 2008-06-06 | 2014-06-18 | クォーク ファーマシューティカルズ インコーポレーティッド | 耳障害治療のための組成物および方法 |
| KR101835889B1 (ko) * | 2009-05-06 | 2018-03-08 | 큐알엔에이, 인크. | 지질 수송 및 대사 유전자에 대한 천연 안티센스 전사체의 억제에 의해 지질 수송 및 대사 유전자 관련된 질환의 치료 |
| ES2646097T3 (es) * | 2009-08-27 | 2017-12-12 | Idera Pharmaceuticals, Inc. | Composición para inhibir la expresión de genes y sus usos |
| US20150141320A1 (en) * | 2012-05-16 | 2015-05-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
| US20150337030A1 (en) * | 2012-05-31 | 2015-11-26 | The Trustees Of Columbia University In The City Of New York | Methods to treat alzheimer's disease using apoe inhibitors |
| WO2016064895A1 (en) * | 2014-10-20 | 2016-04-28 | The Brigham And Women's Hospital, Inc. | Targeting apolipoprotein e (apoe) in neurologic disease |
| JP2019503394A (ja) * | 2016-01-31 | 2019-02-07 | ユニバーシティ・オブ・マサチューセッツＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ | 分岐オリゴヌクレオチド |
| US20210340533A1 (en) * | 2019-12-23 | 2021-11-04 | University Of Massachusetts | Oligonucleotides for tissue specific gene expression modulation |
-
2020
- 2020-03-13 WO PCT/US2020/022748 patent/WO2020190768A1/en unknown
- 2020-03-13 JP JP2021555491A patent/JP2022525208A/ja active Pending
- 2020-03-13 CA CA3133241A patent/CA3133241A1/en active Pending
- 2020-03-13 EP EP20772940.1A patent/EP3937951A4/en active Pending
- 2020-03-13 CN CN202080036085.2A patent/CN113811311A/zh active Pending
- 2020-03-13 US US16/818,563 patent/US20200362341A1/en active Pending
- 2020-03-13 AU AU2020239987A patent/AU2020239987A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10538763B2 (en) | Compounds and methods for modulation of DUX4 | |
| JP2018516091A5 (ru) | ||
| JP2019214587A5 (ru) | ||
| CN106983768B (zh) | 用于在对象中调节smn2剪接的组合物和方法 | |
| CA2866392C (en) | Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome | |
| KR20080031164A (ko) | ＳＲ 단백질의 결합의 방해에 의해 그리고 이차 ＲＮＡ구조의 방해에 의한 ｐｒｅ－ｍＲＮＡ에서 엑손 인식의조절 | |
| JP2023539341A (ja) | Ｄｕｘ４阻害剤およびその使用方法 | |
| JP2022518929A (ja) | Ａｐｐの発現を低減するための化合物及び方法 | |
| JPWO2019181946A1 (ja) | 毒性が軽減した核酸 | |
| JP2022188237A (ja) | 転写プロセシングの調節のための化合物及び方法 | |
| JPWO2020190768A5 (ru) | ||
| JP6934695B2 (ja) | 核酸医薬とその使用 | |
| JPWO2020033899A5 (ru) | ||
| JPWO2020041769A5 (ru) | ||
| JPWO2020205605A5 (ru) | ||
| JPWO2021195307A5 (ru) | ||
| CA3132388A1 (en) | Compositions and methods for treating huntington's disease | |
| WO2021157730A1 (ja) | 核酸医薬とその使用 | |
| WO2022250050A1 (ja) | ｓｃｐＢＮＡ又はＡｍＮＡを含むヘテロ核酸 | |
| WO2023042876A1 (ja) | ２'－修飾ヌクレオシドを含むヘテロ核酸 | |
| WO2023022229A1 (ja) | モルホリノ核酸を含む修飾ヘテロ核酸 | |
| JP7208911B2 (ja) | 核酸分子発現の調節 | |
| WO2021070959A1 (ja) | 修飾ヘテロ核酸 | |
| JPWO2021216556A5 (ru) | ||
| Riasi et al. | Gene silencing method based on DNA |